Effect of Fraxetin on Proliferation and Apoptosis in Breast Cancer Cells

Overview

Journal Oncol Lett

Specialty Oncology

Date 2018 Jan 19

PMID 29344176

Citations 17

Authors

Guodong Liu

Zhenfang Liu

Yuexiang Yan

Haiyan Wang

Affiliations

Soon will be listed here.

Abstract

The aim of the present study was to examine the effect of fraxetin on proliferation and apoptosis in the MCF-7 breast cancer cell line. Cell proliferation was measused using an MTT assay and 4',6-diamidino-2-phenylindole (DAPI) staining was used to determine shrinkage and condensation. RT-PCR was used to examine the expression of factor-associated suicide () and Fas ligand () mRNA, and western blot analysis was used to examine Bax and Bcl-2 protein. MTT showed that the proliferation of MCF-7 cells was significantly inhibited by fraxetin in a dose-dependent manner. Fraxetin also induced significant morphological changes of MCF-7 cells, suggestive of apoptosis, whereas DAPI staining showed that fraxetin caused cell shrinkage and chromatin condensation. RT-PCR showed that the expression of and mRNA was upregulated by fraxetin and the western blot analysis revealed that Bax was upregulated and Bcl-2 was downregulated. In conclusion, fraxetin can inhibit the proliferation of MCF-7 cells, induce apoptosis, upregulate and Bax, and downregulate Bcl-2 to induce apoptosis. These results support the potential therapeutic role for fraxetin in breast cancer.

Citing Articles

Novel strategy for activating gene expression through triplex DNA formation targeting epigenetically suppressed genes.

Notomi R, Sasaki S, Taniguchi Y RSC Chem Biol. 2024; 5(9):884-890.

PMID: 39211471 PMC: 11353075. DOI: 10.1039/d4cb00134f.

Exploration of the mechanism of fraxetin in treating acute myeloid leukemia based on network pharmacology and experimental verification.

Chai Y, Sun X, Zhou Q, Li H, Xi Y Heliyon. 2024; 10(15):e34717.

PMID: 39166080 PMC: 11334658. DOI: 10.1016/j.heliyon.2024.e34717.

Coumarin as an Elite Scaffold in Anti-Breast Cancer Drug Development: Design Strategies, Mechanistic Insights, and Structure-Activity Relationships.

Singh A, Singh K, Kaur K, Singh A, Sharma A, Kaur K Biomedicines. 2024; 12(6).

PMID: 38927399 PMC: 11200728. DOI: 10.3390/biomedicines12061192.

Exploring the mechanism of fraxetin against acute myeloid leukemia through cell experiments and network pharmacology.

Fang T, Liu L, Liu W BMC Complement Med Ther. 2024; 24(1):226.

PMID: 38858650 PMC: 11163689. DOI: 10.1186/s12906-024-04529-8.

LC-MS profiling, in vitro and in silico C-ABL kinase inhibitory approach to identify potential anticancer agents from Dalbergia sissoo leaves.

Naik H, Kanjariya D, Parveen S, Ahmed I, Meena A, Patel H Sci Rep. 2024; 14(1):73.

PMID: 38167560 PMC: 10761914. DOI: 10.1038/s41598-023-49995-1.

References

Finn G, Creaven B, Egan D . Daphnetin induced differentiation of human renal carcinoma cells and its mediation by p38 mitogen-activated protein kinase. Biochem Pharmacol. 2004; 67(9):1779-88. DOI: 10.1016/j.bcp.2004.01.014. View

Xi S, Dyer K, Kimak M, Zhang Q, Gooding W, Chaillet J . Decreased STAT1 expression by promoter methylation in squamous cell carcinogenesis. J Natl Cancer Inst. 2006; 98(3):181-9. DOI: 10.1093/jnci/djj020. View

Ryan A, Shanahan F, OConnell J, Houston A . Fas ligand promotes tumor immune evasion of colon cancer in vivo. Cell Cycle. 2006; 5(3):246-9. DOI: 10.4161/cc.5.3.2413. View

Amatya B, Khan F, Galea M . Optimizing post-acute care in breast cancer survivors: a rehabilitation perspective. J Multidiscip Healthc. 2017; 10:347-357. PMC: 5587162. DOI: 10.2147/JMDH.S117362. View

Korkolopoulou P, Saetta A, Levidou G, Gigelou F, Lazaris A, Thymara I . c-FLIP expression in colorectal carcinomas: association with Fas/FasL expression and prognostic implications. Histopathology. 2007; 51(2):150-6. DOI: 10.1111/j.1365-2559.2007.02723.x. View

McGuire W . Breast cancer prognostic factors: evaluation guidelines. J Natl Cancer Inst. 1991; 83(3):154-5. DOI: 10.1093/jnci/83.3.154. View

Abrahamsen J, Bakken A, Bruserud O, Gjertsen B . Flow cytometric measurement of apoptosis and necrosis in cryopreserved PBPC concentrates from patients with malignant diseases. Bone Marrow Transplant. 2002; 29(2):165-71. DOI: 10.1038/sj.bmt.1703346. View

Cory S, Huang D, Adams J . The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene. 2003; 22(53):8590-607. DOI: 10.1038/sj.onc.1207102. View

Venditto V, Simanek E . Cancer therapies utilizing the camptothecins: a review of the in vivo literature. Mol Pharm. 2010; 7(2):307-49. PMC: 3733266. DOI: 10.1021/mp900243b. View

10.

Kaneko T, Tahara S, Takabayashi F . Inhibitory effect of natural coumarin compounds, esculetin and esculin, on oxidative DNA damage and formation of aberrant crypt foci and tumors induced by 1,2-dimethylhydrazine in rat colons. Biol Pharm Bull. 2007; 30(11):2052-7. DOI: 10.1248/bpb.30.2052. View

11.

Zwick E, Bange J, Ullrich A . Receptor tyrosine kinases as targets for anticancer drugs. Trends Mol Med. 2002; 8(1):17-23. DOI: 10.1016/s1471-4914(01)02217-1. View

12.

Brady H, Gil-Gomez G . Bax. The pro-apoptotic Bcl-2 family member, Bax. Int J Biochem Cell Biol. 1998; 30(6):647-50. DOI: 10.1016/s1357-2725(98)00006-5. View

13.

Chang J, Hsu Y, Kuo P, Chiang L, Lin C . Upregulation of Fas/Fas ligand-mediated apoptosis by gossypol in an immortalized human alveolar lung cancer cell line. Clin Exp Pharmacol Physiol. 2004; 31(10):716-22. DOI: 10.1111/j.1440-1681.2004.04078.x. View

14.

Myong N . Tissue microarray analysis of Fas and FasL expressions in human non-small cell lung carcinomas; with reference to the p53 and bcl-2 overexpressions. J Korean Med Sci. 2005; 20(5):770-6. PMC: 2779273. DOI: 10.3346/jkms.2005.20.5.770. View

15.

Shimada H, Takeda A, Arima M, Okazumi S, Matsubara H, Nabeya Y . Serum p53 antibody is a useful tumor marker in superficial esophageal squamous cell carcinoma. Cancer. 2000; 89(8):1677-83. View

16.

Olaku O, White J . Herbal therapy use by cancer patients: a literature review on case reports. Eur J Cancer. 2010; 47(4):508-14. PMC: 3057114. DOI: 10.1016/j.ejca.2010.11.018. View

17.

Lu Q, Abel P, Foster C, Lalani E . bcl-2: role in epithelial differentiation and oncogenesis. Hum Pathol. 1996; 27(2):102-10. DOI: 10.1016/s0046-8177(96)90362-7. View

18.

Jimenez-Orozco F, Lopez-Gonzalez J, Velasco-Velazquez M, Molina-Guarneros J, MANDOKI J . Decrease of cyclin D1 in the human lung adenocarcinoma cell line A-427 by 7-hydroxycoumarin. Lung Cancer. 2001; 34(2):185-94. DOI: 10.1016/s0169-5002(01)00263-x. View

19.

Thoennissen N, Iwanski G, Doan N, Okamoto R, Lin P, Abbassi S . Cucurbitacin B induces apoptosis by inhibition of the JAK/STAT pathway and potentiates antiproliferative effects of gemcitabine on pancreatic cancer cells. Cancer Res. 2009; 69(14):5876-84. DOI: 10.1158/0008-5472.CAN-09-0536. View

20.

Kim S, Ahn K, Jeong S, Kwon T, Jung J, Yun S . Janus activated kinase 2/signal transducer and activator of transcription 3 pathway mediates icariside II-induced apoptosis in U266 multiple myeloma cells. Eur J Pharmacol. 2010; 654(1):10-6. DOI: 10.1016/j.ejphar.2010.11.032. View